Patent ID: 7754734

Claim:
A method of alleviating a lymphoproliferative disorder in a human patient, the method comprising administering to the patient, in an amount sufficient to alleviate the disorder, a rapamycin derivative having the chemical structure wherein X is (H, H) or O; Y is (H, OH) or O; R 1 is selected from the group consisting of alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl, and (R 3 ) 3 Si; R 2 is selected from the group consisting of —H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl, and (R 3 ) 3 Si; each R 3 is independently selected from the group consisting of —H, methyl, ethyl, isopropyl, tert-butyl, and phenyl; and either R 4 is methyl or R 4 and R 1 together form a C 2-5 alkylene moiety, wherein the lymphoproliferative disorder is selected from the group consisting of a post-transplant lymphoproliferative disorder, and a disorder characterized by proliferation of lymphocytes that have been infected with an Epstein-Barr virus.